South Asian Diabetes Risk: Why BMI Rules Can Limit GLP-1

Why does diabetes screening start at a lower BMI for Asian adults?

The American Diabetes Association recommends considering diabetes testing in adults with a BMI of at least 23 kg/m² if they have Asian ancestry and additional qualifying risk factors; Asian American ancestry is itself among the listed risk factors. The corresponding BMI threshold for other adults is generally 25. These are criteria for considering blood testing, not a diagnosis of diabetes or an automatic recommendation for medication. See the [ADA diabetes screening recommendations](https://doi.org/10.2337/dc26-s002).

BMI relates weight to height but does not directly measure body fat or its distribution. The ADA's obesity guidance therefore incorporates waist measurements and lower thresholds for people with Asian backgrounds, explicitly including South Asian populations. This supports a more complete assessment than weight alone: a person can warrant evaluation even when their BMI falls below conventional obesity thresholds. Population-based thresholds help clinicians identify risk, but they do not determine an individual's health without further assessment. See the [ADA obesity assessment guidance](https://diabetesjournals.org/docm-care/article/doi/10.2337/doci26-0003/170058/Screening-Diagnosis-Evaluation-and-Staging-of).

Why can GLP-1 weight-loss treatment require a higher BMI?

The National Institute of Diabetes and Digestive and Kidney Diseases describes common adult weight-management medication criteria as BMI 30 or above, or BMI 27 or above with a weight-related condition such as hypertension or type 2 diabetes. Therefore, saying that everyone must reach BMI 30 is incomplete. Nevertheless, an Asian adult with BMI 24 may meet diabetes-screening criteria while remaining below these commonly used medication thresholds. See the [NIDDK guide to prescription weight-management medicines](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity).

Drug approval and insurance payment are also separate decisions. The FDA's original Wegovy weight-management approval used the 30-or-27 framework, with an accompanying condition required at the lower threshold. A screening recommendation cannot by itself establish that a particular medicine's benefits outweigh its risks for every person below those cutoffs. Equally, the difference between thresholds raises a legitimate research question: how should treatment eligibility account for metabolic risk that occurs at lower BMI? A physician's personal account illustrates that concern but cannot establish how frequently patients encounter it. See the [FDA review describing Wegovy's original eligibility criteria](https://www.fda.gov/media/185422/download).

What should patients discuss if their diabetes risk seems higher than their BMI suggests?

A useful consultation separates three questions: whether testing is indicated, whether a condition has been diagnosed, and which treatments are appropriate. Waist measurements, weight history and obesity-related complications can add information beyond BMI. The ADA's newer obesity guidance recognizes this broader assessment, but a clinical classification does not automatically establish eligibility under every medication label or insurance plan. See the [ADA guidance on evaluating obesity](https://diabetesjournals.org/docm-care/article/doi/10.2337/doci26-0003/170058/Screening-Diagnosis-Evaluation-and-Staging-of).

For someone with established type 2 diabetes, the prescribing question changes. Ozempic's FDA-approved indication for improving blood glucose in adults with type 2 diabetes does not require BMI 30. However, being eligible for diabetes treatment does not make a particular GLP-1 medicine the best choice for everyone: the clinician must consider medical history, treatment goals and adverse effects, including gastrointestinal symptoms. See the [FDA Ozempic prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf).

If payment is denied, patients can request the written reason and ask their clinician to check which indication and coverage requirements were considered. Meanwhile, care can include individualized nutrition and activity support and management of identified health problems. The practical aim is to address measurable risk while making the distinction between screening, treatment eligibility and coverage clear. The [NIDDK medication guide](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) discusses both treatment planning and insurance considerations.